Summit Trail Advisors, LLC Apellis Pharmaceuticals, Inc. Transaction History
Summit Trail Advisors, LLC
- $3.71 Billion
- Q1 2024
A detailed history of Summit Trail Advisors, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Summit Trail Advisors, LLC holds 4,465 shares of APLS stock, worth $171,277. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,465Holding current value
$171,277% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding APLS
# of Institutions
337Shares Held
111MCall Options Held
1.26MPut Options Held
1.14M-
Wellington Management Group LLP Boston, MA15.1MShares$578 Million0.16% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.4MShares$436 Million19.04% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$426 Million7.87% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.51MShares$365 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$211 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $4.21B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...